Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 European Association for the Study of the Liver (EASL) Congress

Posted on by

– Three posters highlight research on outcomes of TERLIVAZ treatment in key subpopulations of adults with HRS with rapid reduction in kidney function1 – DUBLIN, June 5, 2024 /PRNewswire/ — Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.